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Outline 
• Health systems of East Asian countries, like many others 
across the globe, must confront challenges associated with 
demographic and epidemiologic transition.   
– With populations enjoying longer, healthier lives, societies are 
rapidly aging and adjusting to large burdens of chronic non-
communicable disease. 
– Social case for strengthening healthcare financing, especially for 
vulnerable elderly in poorer areas 
• Need for shift to integrated/ coordinated primary care and 
“value for money” 
– Importance of payment incentives 
– Prescribing and dispensing tradition 
– Measuring and rewarding value: Illustrative  
study for diabetes in Japan 
 
China’s dramatic change 
• Early Mao era: half a billion, 36% age less 
than 15, 80% rural, one-third illiterate, and 
living in absolute poverty.  
• By 2010: 1.3397 billion; ageing (13.3% over 
age 60 and only 16.6% below age 15); half 
(49.7%) urban; 96% literate, with 23% 
attaining a high school or college education. 
• Middle income, 3 decades of unprecedented 
economic growth.  
Karen Eggleston, Stanford 
 
Three Intertwined Transitions 
• Demographic transition 
– Soon, China’s 65+ pop > total current US pop   
• Epidemiologic/health/nutrition transition 
– From infectious to non-communicable chronic disease 
– Urbanization, sedentary lifestyles 
• Economic system transition (central planning to 
market-based economy)  and/or economic 
development (e.g. agricultural rural economy to 
manufacturing- and service-based urban economy) 
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The Economic Implications of 
Population Ageing in China and India: 
Introduction to the Special Issue 
The Journal of the Economics of Ageing 
 
By 
 David E. Bloom and Karen N. Eggleston 
 
Demographic Transition and  
Economic Growth 
• “Demographic dividend” – a one-time boost in GDP per 
capita – when the working-age share of the population 
is relatively high, if that population is productively 
employed (Bloom et al.) 
– Estimated to account for 15% to 26% of China’s rapid growth since 
1970s (Wang and Mason; Bloom et al.; Cai Fang; Aoki) 
 
• Increased nutrition, education, and skills per child can 
enable sustained economic growth  
• Spurs productivity in combination with  
– urbanization  
– industrialization  
– “catch-up” in technology 
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The New Demographic Transition: 
Most Gains in Life Expectancy Now 
Realized Late in Life 
Karen Eggleston and Victor Fuchs  
Journal of Economic Perspectives 
2012 26(3): 137-56. 
 
• The share of increases in life expectancy realized after age 
65 was only about 20 percent at the beginning of the 
20th century for the United States and 16 other countries 
at comparable stages of development;  
• but that share was close to 80 percent by the dawn of the 
21st century, and is almost certainly approaching 100 
percent asymptotically.  
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In Europe, over a century… 
In China, just a few decades... 
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Decrease in Male Death Rates by Age Group in China, 1990-2000 and 
2000-10 
Decrease in death rates between 1990 and 2000 Decrease in death rates between 2000 and 2010
• Demographic and epidemiologic change also 
shape work-lives and thus financing of social 
protection programs, with many Asians 
spending a declining share of life expectancy 
in the labor force—raising questions about 
sustainable financing for health insurance and 
long-term care 
The “Longevity Transition” in Asia and 
Select Developing Countries 
Country (Years) Change in years lived past 65 as a 
percentage of change in life expectancy at 
birth, 1990-2010 
Male XLFP/LE, 
2007 
(Illustrative) 
Japan  Males 72.7%, Females 87.0%  54.1% 
South Korea   Males 45.4%, Females 57.1%  52.0% 
China   Males 51.9%, Females 40.6%  57.6% 
Philippines  Males 26.2%, Females 36.0% 59.6% 
Indonesia  Males 26.1%, Females 35.7% 64.5% 
Brazil  Males 34.2%, Females 35.0% 59.1% 
Vietnam  Males 32.5%, Females 34.7% 54.6% 
India  Males 23.6%, Females 25.8% 60.0% 
Bangladesh  Males 20.7%, Females 25.4% 60.9% 
Based on recent life tables acquired from the US Census Bureau. Eggleston Fuchs 2012 
Will the new demographic transition inevitably 
lead to slower economic growth and crises of 
sustainability (e.g. Europe, Japan)? 
• Enlightened people, foreseeing longer lives, 
might choose to work longer, save more, 
and/or invest in human capital in sufficient 
amounts and innovative enough ways that 
longer lives contribute to increased prosperity. 
• Will East Asia choose to do so? 
Eggleston Fuchs 2012 
Elderly Health and Long-Term Care Needs: 
Recent Evidence from CHARLS baseline 
(China Health and Retirement Longitudinal Study 2011) 
• Among 60+, 31.8% report poor health; 
• 38.1% report a disability; 
• 23.8% report requiring assistance with basic daily 
activities;  
• 33.4% experience bodily pain.  
• 10.7% underweight; 28.0% overweight, of which 
4.5% were obese; and  
• 54.0% had hypertension (30-40% undiagnosed, 
higher in rural areas). 
• Women in worse health (although live longer). 
 
 
Source: CHARLS Team, May 2013,  Challenges of Population Aging in China: Evidence from the National Baseline Survey of the  
China Health and Retirement Longitudinal Study (CHARLS)  
Chronic Disease Burden 
 In “The Macroeconomic Impact of Non-communicable 
Diseases in China and India: Estimates, Projections, and 
Comparisons,” Bloom et al. (Journal of the Economics of 
Aging 2014) study the impact of five non-communicable 
diseases (NCDs) on the projected economic performance of 
China and India from 2012-2030 
 China projected to incur a financial burden approximately five 
times greater than India.  
 In aggregate, the financial expenditure for the measured NCDs 
over the 19-year timeframe is US$23.02 trillion for China.  
17 

+ Simulating Future Disease Prevalence 
with “Future Elderly Model” for Japan 
Brian Chen, Hawre Jalal, Karen Eggleston, Michael Hurley, Lena Schoemaker, and 
Jay Bhattacharya, November 2014 Stanford working paper 
Health Spending Per Capita, 2011, OECD 
 
OECD Health Data 2013, How Does China Compare with OECD Countries 
 
+ 
To adapt to this new reality, 
substantial policy priority should 
be placed on strengthening 
primary care and enhancing 
value-for-money in the health 
sector. 
 
 
21 
+ 
The quality of primary care providers  in China is 
highly heterogeneous. 
 
 Earning patients’ trust 
 Training and ongoing clinical updating 
 Work effectively with hospitals (‘two-way referral system’)  
 Importance of payment incentives and contracting to meet 
these goals 
 
 
22 
+ Four core domains of primary care, each with two subdomains: 
a structure-related subdomain (capacity to provide needed 
services) and a behavior-related subdomain (service is 
provided when needed)  
 
 
• Serves as 
usual entry 
point into 
the health 
care system 
• Must be 
accessible 
(structural) & 
used 
(behavioral) 
 
 
• Long-term 
relationship 
with mutual 
realization of 
expectations 
and needs 
• Requires a 
population 
registry and 
an ongoing 
person-
focused 
relationship 
 
 
• Availability 
and 
recognition 
of 
information 
about prior 
and existing 
problems for 
current care 
 
 
• Provision of 
preventive 
and curative 
health 
services and 
facilities 
 
23 
First Contact 
Care 
Continuous  
Care 
Co-ordinated 
Care 
Comprehensive 
Care 
Barbara Starfield and colleagues, Primary Care Assessment Tool 
+ 
Case Study: Shandong, China 
Aim and Data 
To study the effectiveness of contracting for primary care with 
community health centers, including private providers  
 Data sources: One, administrative records at the municipal 
and provincial levels; two, a household survey of 1013 
community residents in Weifang and 681 residents in City Y; 
and three, a provider survey of 1298 staff at official 
community health stations (CHS) in Weifang and City Y 
 Patients’ scores  based on a locally contextualized PCAT, 
anonymous questionnaires to staff members in CHS, and one-
on-one, in-depth interviews for qualitative data 
 Conducted in November 2009 
24 
Source: Wang et al. 2013. “Contracting with private providers for primary care services: evidence from urban China”. Health 
Economics Review 2013, 3: p.1-20 
+ 
 Residents do not trust community health stations 
generally and tend to do a routine health exam there only if 
they were of low socioeconomic status  
 Improved provider payment methods should be 
considered  
 to minimize the unintended consequences under fee-for-service 
for services not explicitly rewarded in the performance contract 
and  
 reverse the over-focus on curative care and relative neglect 
towards preventive health services and population health 
outreach services  
25 
Source: Wang et al. 2013. “Contracting with private providers for primary care services: evidence from urban China”. Health 
Economics Review 2013, 3: p.1-20 
Case Study: Shandong, China 
Results and Conclusions 
Limited Evidence on Provider Payment 
Reforms away from FFS in Asia 
 • Like non-Asian OECD countries, most Asian 
countries have been seeking methods to 
constrain rapid health expenditure growth while 
improving quality and access 
– Demand-side cost sharing (yet well known drawbacks: 
barrier to access for the poor) 
– Supply-side cost sharing 
• Case-based payments, e.g. DRG for hospitals 
• Capitation (e.g. Thailand achieving universal coverage) 
• Global budgets (e.g. Taiwan) 
– Some experiments with P4P, little measure of “value” 
• Tsai. et al. (2010) "P4P on TB" program improved the 
treatment default rate for TB patients in Taiwan, 2002 to 
2005.  
Tsai, W. C., P. T. Kung, M. Khan, C. Campbell, W. T. Yang, T. F. Lee, and Y. H. Li. 2010. "Effects of Pay-for-Performance 
System on Tuberculosis Default Cases Control and Treatment in Taiwan" The Journal of infection, 61(3): 235-243. 
Physician-dispensing in Asia 
• Traditionally, physician payment was for drugs: 
• “It was considered morally unacceptable to 
accept fees for performing a humane service” 
[diagnosis] (Ikegami 2005, p.124) 
 
Evidence of profit-related prescribing 
in China 
• Currie, Lin, and Zhang (2010 JHE) audit the antibiotic prescribing 
behavior of hospital-based physicians in two cities and one rural 
area using student "simulated patients" during the 2008 and 
2009 flu seasons.  
• They find that Chinese physicians prescribe antibiotics for a 
startlingly high proportion of patients (averaging 62%), even 
when patients report symptoms that do not warrant antibiotics;  
• 39% of physicians still prescribed antibiotics when the simulated 
patients signaled to doctors that they knew that taking 
antibiotics would be inappropriate. 
• In follow-on study, found the over-prescription greatly reduced 
when profit incentive removed (because “patient” said would 
buy the drug elsewhere) 
Managing chronic disease in rural China:  
Will lowering drug copayments enhance adherence 
and improve outcomes? 
 
 Karen Eggleston, Stanford University and NBER 
Wang Yan, Shandong Department of Health 
Jinan Zhang, Stanford University 
 
Preliminary results 
+ 
Research questions 
We study a county in Shandong Province that 
began in July 2010 distributing free 
antihypertensive medications to all residents 
over age 60 with diagnosed hypertension. 
Utilizing unique patient-level clinical and 
spending data from this natural experiment in 
rural China, we study the impact of lowering 
patient co-payments for anti-hypertensives on 
total and out-of-pocket medical spending, as well 
as self-reported health and medication 
adherence. 
 
+ 
The poorest elderly patients 
benefit 
 For the poorest-income quartile patients with hypertension, 
reduction in spending 
 medication spending 
 overall spending  
 out-of-pocket burden for the most vulnerable patients 
 Self-reported blood pressure, self-assessed health, and 
general well-being do not differ significantly from 
comparison group 
 May be too early to see any effect, or self reports are not accurate 
or sensitive enough to detect 
 If lower spending leads to better adherence, have reason to 
expect improved blood pressure control in future for this 
vulnerable population (elderly poor in rural areas) 
 
The net value of health screening and 
incentives for management of 
diabetes and hypertension in Japan, 
2008-2012  
 
Karen Eggleston and Toshiaki Iizuka  
Stanford University and University of Tokyo 
Preliminary results, as presented at ECHE conference in Dublin, July 
2014 
+ 
Background  
 
 Japan is emblematic of the age of longevity 
 Highest proportion of elderly adults in the world 
 Low fertility and increased longevity  population declining 
(projected to decline to 87 million by 2060) 
 40% of population over 65 by 2060 
 Policymakers searching for strategies 
 Enhance healthcare productivity  and improve “value for money” 
in chronic disease management 
 Improve health through prevention (e.g. mandatory annual health 
check-ups) to help compress morbidity and delay onset of 
chronic disease 
 For this presentation, focus on the results regarding diabetes 
+ 
Research questions 
 Has the net value of treatment for diabetes increased in 
Japan? 
 Is increased spending associated with commensurate 
improvements in quality?  
 Is healthcare productivity increasing? 
 Is healthcare inflation over-estimated because it is not adjusted 
for quality improvements? 
 
 Do individuals respond to the signals embodied in regular 
health screening such as Japan’s annual mandatory health 
screening program, and do responses increase net value? 
 Is there a causal link between increased input use and improved 
outcomes? 
 Regression discontinuity analyses, using clinical thresholds of 
diagnosis to approximate random assignment  
 
 
+ 
Previous literature on net value 
 Research dating back to the pioneering work of 
Scitovsky (1965) measures the value of health care 
spending not with inputs but with the desired output: 
cure or management of a specific medical condition 
Most studies focus on acute conditions  
 Cutler, McClellan, Newhouse and Remler (1998): estimate that a 
quality-adjusted price index for heart attack treatments 
declined about 1 percent annually between 1983 and 1994.   
 Berndt, Bir, Busch, Frank, and Normand (2002) similarly find that 
the incremental cost of treating an episode of acute phase 
major depression fell between 1991 and 1996.   
 Focusing on cataract surgery between 1969 and 1993, Shapiro, 
Shapiro, and Wilcox (2001) find that spending has not increased 
faster than the general price level.  
+ 
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+ 
Net value of chronic care 
 Constant et al. (2006): quality-adjusted price index for 
cancer treatment declined by 5.4% annually between 1995 
and 2003. 
 Examining colorectal cancer drugs, Lucarelli and Nicholson 
(2009) estimate that two quality-adjusted price indices 
were roughly constant between 1993 and 2005.  
 Eggleston et al. (2009): benefits of the additional or newer 
care for diabetes in the US outweighed the greater costs for 
the average patient between 1997 and 2005. 
 No similar studies yet in Asia (requires detailed data on 
clinical metrics such as blood pressure and HbA1c to value 
quality change, as well as total spending) 
 
 
+ 
Data 
 13,322 employees with Diabetes (DM) from JMDC 
database  
 Total annual medical spending (from medical 
claims including drugs), matched with detailed 
clinical data from ICD10 codes and annual 
mandatory health check-ups 
 Five-year period 2008-2012 
+ 
Net value: ΔV-ΔC 
 Comparing health care in 2008-09 with that of 2011-12 
 ΔV = monetary value of  
 improvements in health status (lower mortality risk) 
 and, in some specifications, avoided treatment spending from 
lower probability of AMI and stroke 
 ΔC = increase in annual inflation-adjusted treatment 
spending  
 Total medical spending, based on actual claims 
 2010 ¥ using the CPI all-items index to convert monthly 
spending to real yen 
 
 If ΔV-ΔC>0,  society is obtaining value for 
its money 
 
 
+ 
Measuring outcomes: ΔV 
 Cardiovascular risks (coronary 
heart disease, stroke) and non-
cardiovascular mortality risk, 
using the JJ risk engine 
published equations (Tanaka et 
al., Diabetes Care 2013) 
 Age 
 Sex 
 HbA1c 
 BMI 
 Systolic blood pressure 
 Non-HDL cholesterol 
 Smoking status 
 Leisure time physical activity 
 for stroke, atrial fibrillation 
  
 “Modifiable Risk” 
measures: hold age 
and duration of 
diabetes constant at 
their values at cohort 
entry.  
 These “modifiable 
risk” measures reflect 
the risk factors 
amenable to change 
through clinical care.  
 
+ 
Valuing health improvements 
Assume $200,000 per life year 
Sensitivity analyses: $50,000-$300,000 
  Three approaches 
1. By baseline age cohort 
2. Weighted average across age cohorts 
3. Individual patient level calculations 
 
+ 
Preliminary results 
 [Cannot post exact numbers before publication, but…] 
 Spending increased 
 Quality improved 
 All estimates of net value were positive, albeit small 
+ 
Conservative estimates 
(1) Ignore better quality of life and reduced probability of 
other adverse endpoints, such as blindness or amputation;  
(2) Mortality risk probably increasing over time rather than 20 
percent of the predicted risk each of 5 years and zero 
thereafter (discounted at 3% for 20 years);  
(3) Spending = all medical spending (no attempt to isolate the 
fraction of spending directly attributable to diabetes). 
(4) Sample is employed population, with net value increasing 
by age, suggesting that including the net value for those in 
70s and 80s (a large and growing population in Japan) would 
increase overall net value estimate. 
+ 
Limitations 
 Only includes the working-age population in Japan 
 Only includes those with valid health check-up data in 
baseline and final periods (albeit bias mitigated because 
check-ups are mandatory) 
 Not necessarily nationally representative  
 JJ risk engine not yet widely validated, and does not predict 
fatal CHD and fatal stroke risk – we supplemented with 
estimates from our data 
 Does not include value of work productivity (less absenteeism 
and “presenteeism” – future research topic) 
 
+ 
Implications of net value estimates 
 First study of net value of chronic disease 
management in Asia. 
 Similar to the US, the unit cost of treatment for 
diabetes—adjusting for the value of health 
outcomes—has been roughly constant, if not 
decreasing, in Japan. 
 Since input prices for health care have not been 
declining, our results are consistent with 
productivity improvement in health care. 
 Remaining question: how much of the positive net 
value of increased spending is causal? Regression 
discontinuity analyses help to address… 
+ 
Cost benefit analysis of DM treatment: the 
Regression Discontinuity (RD) approach 
 Health checkup results (e.g., HbA1c, FBS) just below and above a threshold may be 
viewed as random  
 Patients with just above the threshold value (e.g., HbA1c≥6.5) may receive more care 
(inputs) than those just below the threshold 
 We count the following inputs for the 12 months after a checkup 
 1) DM-related physicians visits and hospital days, 2) HbA1c exam, 3) DM diagnosis, 4) use 
of DM drugs, and 5) DM-related medical expenditures 
 Additional care may lead to better health outcomes for the patients just above the 
threshold 
 Lower HbA1c and FBS values the next year. 
 Lower cardiovascular risk and non-CVD mortality from JJ risk engine. 
 Lower CVD mortality risk as developed for the net value analyses (JJ risk engine + our 
estimates) 
 By comparing the inputs & outcomes, we can compute the cost-benefit of providing DM 
care at the threshold.     
 This approach is similar to Almond et al. (2010) “Estimating marginal returns to medical 
care: Evidence from at-risk newborns,” QJE  
46 
+ 
Data used in the RD analysis 
 We include a checkup in the sample if it meets the following 
6 conditions.  
1. A checkup was conducted between 2008 and 2011 
2. The patient had a checkup only once in a year 
3. Claims data of the patient exist for at least 6 months before the 
checkup. 
4. Claims data of the patient exist for at least 12 months after the 
checkup. 
5. The patient was not diagnosed as DM during the 6 months before 
the checkup (i.e., we focus on non-DM patients)  
6. The patient was 30～64 years old at the checkup. 
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Graphical presentation of RD design 
Average (or rate) of outcome 
variable for each value group 
in the year after the check-up 
Health metric from health 
checkup, average by group 
Threshold line ex) HbA1c = 
6.2 
Quadratic fitting 
for both sides of 
the threshold 
48 
Results: Regression analysis 
(2-dimensions, HbA1c=6.3 or FBS=126) 
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 Crossing the threshold leads to:  
 A small, but statistically significant improvement in the intermediate 
outcome measures next year, in most of the specifications 
 Decrease in next year’s FBS 
 Decrease in next year’s HbA1c 
 Increase in the following input measures, especially when we use a 
wider window (with more observations) 
 # of DM-related office visits or hospital days 
 Probability of use of DM drugs 
 DM-related medical expenditures 
 No change in some other input measures, including 
 Probability of DM diagnosis 
 Probability of HbA1c exam 
 Broadly similar results for HbA1c=6.2 & FBS=126 
 
 
 
 
 
 
+ 
Results: Regression analysis of CVD risk 
outcomes 
 RD analyses applied to the next year’s CVD risks as measured 
by the JJ risk engine 
 In some specifications where we use a large number of 
observations, the coefficient of the treatment variable becomes 
negative and significant (at the 5% level) for Stroke_risk.  
 As before, the treatment dummy is defined by the combination of 
HbA1c and FBS thresholds (using HbA1c=6.2 or 6.3 & FBS=126). 
 Point estimate for reduction in Stroke_risk is -0.009 ~ -0.01. 
 Implies a large reduction in risk relative to the sample mean of 
Stroke_risk, which is around 0.03~0.04.  To be explored in further 
sensitivity analyses. 
 RD results support causal interpretation of positive net value 
(improved outcomes not just associated with, but at least 
partially caused by, increased use of inputs) 
+ 
Some conclusions  
 Has the net value of treatment for diabetes increased in 
Japan? 
 Yes, consistent with improving productivity 
 Suggests caution in applying “blunt instruments” to limit 
spending growth – many treatments have positive net value 
 Do individuals respond to the signals embodied in regular 
health screening such as Japan’s annual mandatory health 
screening program? 
 Somewhat – some indication that individuals may improve 
behavior and/or use more medical care to reduce subsequent 
risk of stroke and diabetes complications 
 Much room for further improvement in productivity and in 
health behavior – not clear that making annual check-ups 
mandatory changed  trajectory of health and spending. 
+ 
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